a) Long-lasting responses are generated due to the development of anti-tumour memory, otherwise known as immunotherapy

b) It’s a chemotherapy drug that works by preventing the tumour cells from growing, dividing and making more cells.

c) Stelfonta destroys mast cell tumours via an innovative three fold mechanism that induces an acute inflammatory response, an oncolytic effect on the tumour cells and directly destroys tumour vasculature.

a) Stelfonta works rapidly to cause oncolysis of tumour cells within the first hours of treatment by causing disruption of mitochondrial function and tumour cell membranes.

b) It effectively normalises tumour vasculature and attenuates blood vessel growth otherwise known as anti-angiogenic activity.

a) True

b) False

a) Stelfonta is only indicated for small mast cell tumours below the elbow in dogs.

b) I can only use Stelfonta on a mast cell tumour that is recurrent.

c) It is indicated for non-metastatic cutaneous mast cell tumours (anywhere) and non-metastatic subcutaneous mast cell tumours located at or distal to the elbow/hock in dogs,of any cytological grade, </= 10 cc, accessible to intratumoral injections

a) Administration of concomitant medications is essential for two days prior to Day 1 of Stelfonta treatment

b) The dose of Stelfonta on the day of treatment is determined by the volume of the mast cell tumour and not the weight of the dog.

c) The maximum dose of Stelfonta is 0.25mL/kg body weight, with no more than 5mL administered per dog, regardless of tumour volume or dog body weight.

d) All of the above.